Antibodies to major histocompatibility complex class II antigens directly prime neutrophils and cause acute lung injury in a two-event in vivo rat model

Transfusion

Volumn 56, Issue 12, 2016, Pages 3004-3011

  Kelher, Marguerite R ^a,b   Banerjee, Anirban ^b   Gamboni, Fabia ^b   Anderson, Cameron ^b   Silliman, Christopher C ^a,b,c  

^a Bonfils Blood Center   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Nutrition Obesity Research Center at the University of Colorado   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; FORMYLMETHIONYLLEUCYLPHENYLALANINE; GAMMA INTERFERON; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OX6 ANTIBODY; PROTEIN ANTIBODY; SALMONELLA ENDOTOXIN; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ANTIBODY; CYTOKINE; HLA ANTIGEN CLASS 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CELL ACTIVATION; CELL ISOLATION; CONTROLLED STUDY; FLOW CYTOMETRY; IN VIVO STUDY; LUNG ENDOTHELIUM; MALE; NEUTROPHIL; NONHUMAN; RAT; RESPIRATORY BURST; TRANSFUSION RELATED ACUTE LUNG INJURY; ACUTE LUNG INJURY; ADVERSE EFFECTS; ANIMAL; BLOOD TRANSFUSION; DRUG EFFECTS; ENDOTHELIUM; GENETICS; IMMUNOLOGY; LEUKOCYTE ACTIVATION; METABOLISM; PATHOLOGY;

ACUTE LUNG INJURY; ANIMALS; ANTIBODIES; BLOOD TRANSFUSION; CYTOKINES; ENDOTHELIUM; HISTOCOMPATIBILITY ANTIGENS CLASS II; LIPOPOLYSACCHARIDES; NEUTROPHIL ACTIVATION; NEUTROPHILS; RATS; RESPIRATORY BURST;

EID: 85003480976     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13817     Document Type: Article

References (64)

1. Chapman CE, Stainsby D, Jones H, et al. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion 2009;49:440–52.
2. Eder AF, Benjamin RJ. TRALI risk reduction: donor and component management strategies. J Clin Apher 2009;24:122–9.
3. Eder AF, Herron RM Jr, Strupp A, et al. Effective reduction of transfusion-related acute lung injury risk with male-predominant plasma strategy in the American Red Cross (2006-2008). Transfusion 2010;50:1732–42.
4. Eder AF, Dy BA, Perez JM, et al. The residual risk of transfusion-related acute lung injury at the American Red Cross (2008-2011): limitations of a predominantly male-donor plasma mitigation strategy. Transfusion 2013;53:1442–9.
5. Hendrickson JE, Hillyer CD. Noninfectious serious hazards of transfusion. Anesth Analg 2009;108:759–69.
6. Holness L, Knippen MA, Simmons L, et al. Fatalities caused by TRALI. Transfus Med Rev 2004;18:184–8.
7. Bux J. Antibody-mediated (immune) transfusion-related acute lung injury. Vox Sang 2011;100:122–8.
8. Keller-Stanislawski B, Reil A, Gunay S, et al. Frequency and severity of transfusion-related acute lung injury—German haemovigilance data (2006-2007). Vox Sang 2010;98:70–7.
9. Kao GS, Wood IG, Dorfman DM, et al. Investigations into the role of anti-HLA class II antibodies in TRALI. Transfusion 2003;43:185–91.
10. Kopko PM, Popovsky MA, MacKenzie MR, et al. HLA class II antibodies in transfusion-related acute lung injury. Transfusion 2001;41:1244–8.
11. Nishimura M, Mitsunaga S, Ishikawa Y, et al. Possible mechanisms underlying development of transfusion-related acute lung injury: roles of anti-major histocompatibility complex class II DR antibody. Transfus Med 2003;13:141–7.
12. Sachs UJ, Wasel W, Bayat B, et al. Mechanism of transfusion-related acute lung injury induced by HLA class II antibodies. Blood 2011;117:669–77.
13. Fung YL, Silliman CC. The role of neutrophils in the pathogenesis of transfusion-related acute lung injury. Transfus Med Rev 2009;23:266–83.
14. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 1985;25:573–7.
15. Vella A, Sartoris S, Bambara L, et al. Cell contact-dependent PMN HLA-DR and CD69 membrane expression induced by autologous mono-lymphocytes and cell lines. Inflammation 2002;26:143–52.
16. Cao Y, Schmitz JL, Yang J, et al. DRB1*15 allele is a risk factor for PR3-ANCA disease in African Americans. J Am Soc Nephrol 2011;22:1161–7.
17. Gosselin EJ, Wardwell K, Rigby WF, et al. Induction of MHC class II on human polymorphonuclear neutrophils by granulocyte/macrophage colony-stimulating factor, IFN-gamma, and IL-3. J Immunol 1993;151:1482–90.
18. Mudzinski SP, Christian TP, Guo TL, et al. Expression of HLA-DR (major histocompatibility complex class II) on neutrophils from patients treated with granulocyte-macrophage colony-stimulating factor for mobilization of stem cells. Blood 1995;86:2452–3.
19. Oehler L, Majdic O, Pickl WF, et al. Neutrophil granulocyte-committed cells can be driven to acquire dendritic cell characteristics. J Exp Med 1998;187:1019–28.
20. Porretti L, Coluccio E, Prati D, et al. Flow-cytometric approach to the prompt laboratory diagnosis of TRALI: a case report. Eur J Haematol 2004;73:295–9.
21. Radsak M, Iking-Konert C, Stegmaier S, et al. Polymorphonuclear neutrophils as accessory cells for T-cell activation: major histocompatibility complex class II restricted antigen-dependent induction of T-cell proliferation. Immunology 2000;101:521–30.
22. Reinisch W, Lichtenberger C, Steger G, et al. Donor dependent, interferon-gamma induced HLA-DR expression on human neutrophils in vivo. Clin Exp Immunol 2003;133:476–84.
23. Spagnoli GC, Juretic A, Rosso R, et al. Expression of HLA-DR in granulocytes of polytraumatized patients treated with recombinant human granulocyte macrophage-colony-stimulating factor. Hum Immunol 1995;43:45–50.
24. Hansch GM, Radsak M, Wagner C, et al. Expression of major histocompatibility class II antigens on polymorphonuclear neutrophils in patients with Wegener's granulomatosis. Kidney Int 1999;55:1811–8.
25. Iking-Konert C, Vogt S, Radsak M, et al. Polymorphonuclear neutrophils in Wegener's granulomatosis acquire characteristics of antigen presenting cells. Kidney Int 2001;60:2247–62.
26. Salazar JC, Pope CD, Sellati TJ, et al. Coevolution of markers of innate and adaptive immunity in skin and peripheral blood of patients with erythema migrans. J Immunol 2003; 171:2660–70.
27. Sandilands GP, McCrae J, Hill K, et al. Major histocompatibility complex class II (DR) antigen and costimulatory molecules on in vitro and in vivo activated human polymorphonuclear neutrophils. Immunology 2006;119:562–71.
28. Kelher MR, Masuno T, Moore EE, et al. Plasma from stored packed red blood cells and MHC class I antibodies causes acute lung injury in a 2-event in vivo rat model. Blood 2009;113:2079–87.
29. Silliman CC, Elzi DJ, Ambruso DR, et al. Lysophosphatidylcholines prime the NADPH oxidase and stimulate multiple neutrophil functions through changes in cytosolic calcium. J Leukoc Biol 2003;73:511–24.
30. Akiyama H, Itagaki S, McGeer PL. Major histocompatibility complex antigen expression on rat microglia following epidural kainic acid lesions. J Neurosci Res 1988;20:147–57.
31. Chang SC, Hsu HK, Perng RP, et al. Increased expression of MHC class II antigens in rejecting canine lung allografts. Transplantation 1990;49:1158–63.
32. Nelson DJ, McMenamin C, McWilliam AS, et al. Development of the airway intraepithelial dendritic cell network in the rat from class II major histocompatibility (Ia)-negative precursors: differential regulation of Ia expression at different levels of the respiratory tract. J Exp Med 1994;179:203–12.
33. Suda T, Sato A, Sugiura W, et al. Induction of MHC class II antigens on rat bronchial epithelial cells by interferon-gamma and its effect on antigen presentation. Lung 1995;173:127–37.
34. Ibrahim L, Dominguez M, Yacoub M. Primary human adult lung epithelial cells in vitro: response to interferon-gamma and cytomegalovirus. Immunology 1993;79:119–24.
35. Kittur DS, Wilasrusmee C, Han WF, et al. Locally derived cytokines and upregulation of MHC class II genes in allografts. J Heart Lung Transplant 2002;21:882–9.
36. McDouall RM, Batten P, McCormack A, et al. MHC class II expression on human heart microvascular endothelial cells: exquisite sensitivity to interferon-gamma and natural killer cells. Transplantation 1997;64:1175–80.
37. Silliman CC, Voelkel NF, Allard JD, et al. Plasma and lipids from stored packed red blood cells cause acute lung injury in an animal model. J Clin Invest 1998;101:1458–67.
38. Abdel-Salam BK. T-cell proliferation by surface molecules expression on polymorphonuclear neutrophils stimulated with IL-4 in superantigen presence. Allergol Immunopathol (Madr) 2012;40:81–7.
39. Beauvillain C, Delneste Y, Scotet M, et al. Neutrophils efficiently cross-prime naive T cells in vivo. Blood 2007;110:2965–73.
40. Culshaw S, Millington OR, Brewer JM, et al. Murine neutrophils present class II restricted antigen. Immunol Lett 2008;118:49–54.
41. Fanger NA, Liu C, Guyre PM, et al. Activation of human T cells by major histocompatibility complex class II expressing neutrophils: proliferation in the presence of superantigen, but not tetanus toxoid. Blood 1997;89:4128–35.
42. Geng S, Matsushima H, Okamoto T, et al. Emergence, origin, and function of neutrophil-dendritic cell hybrids in experimentally induced inflammatory lesions in mice. Blood 2013;121:1690–700.
43. Sandilands GP, Ahmed Z, Perry N, et al. Cross-linking of neutrophil CD11b results in rapid cell surface expression of molecules required for antigen presentation and T-cell activation. Immunology 2005;114:354–68.
44. Yamashiro S, Wang JM, Yang D, et al. Expression of CCR6 and CD83 by cytokine-activated human neutrophils. Blood 2000;96:3958–63.
45. Abe S, Seo Y, Hayashi H, et al. Neutrophil adsorption by polymyxin B-immobilized fiber column for acute exacerbation in patients with interstitial pneumonia: a pilot study. Blood Purif 2010;29:321–6.
46. Davey MS, Morgan MP, Liuzzi AR, et al. Microbe-specific unconventional T cells induce human neutrophil differentiation into antigen cross-presenting cells. J Immunol 2014;193:3704–16.
47. Drifte G, Dunn-Siegrist I, Tissieres P, et al. Innate immune functions of immature neutrophils in patients with sepsis and severe systemic inflammatory response syndrome. Crit Care Med 2013;41:820–32.
48. Oliveira R, Napoleao P, Banha J, et al. Crosstalk between inflammation, iron metabolism and endothelial function in Behcet's disease. Clin Hemorheol Microcirc 2014;56:175–85.
49. Tvinnereim AR, Hamilton SE, Harty JT. Neutrophil involvement in cross-priming CD8+ T cell responses to bacterial antigens. J Immunol 2004;173:1994–2002.
50. Zarco MA, Ribera JM, Villamor N, et al. Phenotypic changes in neutrophil granulocytes after G-CSF administration in patients with acute lymphoblastic leukemia under chemotherapy. Haematologica 1998;83:573–5.
51. Khan SY, Kelher MR, Heal JM, et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood 2006;108:2455–62.
52. Silliman CC, Bjornsen AJ, Wyman TH, et al. Plasma and lipids from stored platelets cause acute lung injury in an animal model. Transfusion 2003;43:633–40.
53. Silliman CC, Moore EE, Kelher MR, et al. Identification of lipids that accumulate during the routine storage of prestorage leukoreduced red blood cells and cause acute lung injury. Transfusion 2011;51:2549–54.
54. Silliman CC, Kelher MR, Khan SY, et al. Experimental prestorage filtration removes antibodies and decreases lipids in RBC supernatants mitigating TRALI in vivo. Blood 2014;123:3488–95.
55. Wyman TH, Bjornsen AJ, Elzi DJ, et al. A two-insult in vitro model of PMN-mediated pulmonary endothelial damage: requirements for adherence and chemokine release. Am J Physiol Cell Physiol 2002;283:C1592–603.
56. Aysola AE, Deisting B, Mair DC. Review of 16 blood components from a donor with HLA class II antibodies [abstract]. Transfusion 2005;45(Suppl):83A.
57. Curtis BR. Is TRALI caused by HLA class II too? Blood 2011;117:378–9.
58. Nicolle AL, Chapman CE, Carter V, et al. Transfusion-related acute lung injury caused by two donors with anti-human leucocyte antigen class II antibodies: a look-back investigation. Transfus Med 2004;14:225–30.
59. Nishimura M, Hashimoto S, Satake M, et al. Interference with TRALI-causing anti-HLA DR alloantibody induction of human pulmonary microvascular endothelial cell injury by purified soluble HLA DR. Vox Sang 2007;93:78–82.
60. Nishimura M, Hashimoto S, Takanashi M, et al. Role of anti-human leucocyte antigen class II alloantibody and monocytes in development of transfusion-related acute lung injury. Transfus Med 2007;17:129–34.
61. Varela M, Mas A, Nogues N, et al. TRALI associated with HLA class II antibodies. Transfusion 2002;42:1102.
62. Win N, Brown C, Navarrete C. TRALI associated with HLA class II antibodies. Transfusion 2003;43:545–6.
63. Burg J, Krump-Konvalinkova V, Bittinger F, et al. GM-CSF expression by human lung microvascular endothelial cells: in vitro and in vivo findings. Am J Physiol Lung Cell Mol Physiol 2002;283:L460–7.
64. Lei L, Altstaedt J, von der Ohe M, et al. Induction of interleukin-8 in human neutrophils after MHC class II cross-linking with superantigens. J Leukoc Biol 2001;70:80–6.